Meeting News CoverageVideo

VIDEO: Recently approved Nuplazid fills treatment gap in Parkinson’s disease

ATLANTA — Henry Nasrallah, MD, of the department of neurology and psychiatry at St. Louis University, discusses the utility of the recently FDA-approved Nuplazid for psychosis in Parkinson’s disease.

“Parkinson’s disease has many non-motor psychiatric symptoms, including psychosis. Up to 50% of Parkinson’s patients develop psychotic symptoms, which are predominantly visual hallucinations as well as delusions,” Nasrallah told Healio.com/Psychiatry. “These are obviously very disruptive symptoms and they get worse as disease progresses.”

Until now, there has been no medication intended for psychosis in Parkinson’s disease, according to Nasrallah.

ATLANTA — Henry Nasrallah, MD, of the department of neurology and psychiatry at St. Louis University, discusses the utility of the recently FDA-approved Nuplazid for psychosis in Parkinson’s disease.

“Parkinson’s disease has many non-motor psychiatric symptoms, including psychosis. Up to 50% of Parkinson’s patients develop psychotic symptoms, which are predominantly visual hallucinations as well as delusions,” Nasrallah told Healio.com/Psychiatry. “These are obviously very disruptive symptoms and they get worse as disease progresses.”

Until now, there has been no medication intended for psychosis in Parkinson’s disease, according to Nasrallah.

    See more from Highlights from APA 2016